EGFR is A Potential Therapeutic Target for Highly Glycosylated and Aggressive Pancreatic Neuroendocrine Neoplasms.

pNENs are relative indolent tumors with heterogeneous clinical presentation at diagnosis. It is important to establish aggressive subgroups of pNENs and identify potential therapeutic targets. Patients with pNEN (322 cases) were included to examine the association between glycosylation biomarkers and clinical/pathological traits. The molecular and metabolic features stratified by glycosylation status were assessed by RNA-seq/whole exome sequencing and immunohistochemistry. A considerable proportion of patients had elevated glycosylation biomarkers (carbohydrate antigen [CA] 19-9, 11.9%; CA125, 7.5%; carcinoembryonic antigen [CEA], 12.8%). CA19-9 (hazard ratio [HR] = 2.26, P = 0.019), CA125 (HR = 3.79, P = 0.004), and CEA (HR = 3.16, P = 0.002) were each independent prognostic variables for overall survival. High glycosylation group, defined as pNENs with elevated level of circulating CA19-9, CA125, or CEA, accounted for 23.4% of all pNENs. High glycosylation (HR = 3.14, P = 0.001) was an independent prognostic variable for overall survival and correlated with G3 grade (P < 0.001), poor differentiation (P = 0.001), perineural invasion (P = 0.004), and distant metastasis (P < 0.001). Epidermal growth factor receptor (EGFR) was enriched in high glycosylation pNENs using RNA-seq. EGFR was expressed in 21.2% of pNENs using immunohistochemistry and associated with poor overall survival (P = 0.020). A clinical trial focusing on EGFR expressed pNENs was initiated (NCT05316480). Thus, pNEN with aberrant glycosylation correlates with a dismal outcome and suggests potential therapeutic target of EGFR. This article is protected by copyright. All rights reserved.